Collegium Pharmaceutical Inc (COLL) Insider Paul Brannelly Acquires 10,000 Shares
Collegium Pharmaceutical Inc (NASDAQ:COLL) insider Paul Brannelly purchased 10,000 shares of the company’s stock in a transaction dated Friday, May 12th. The stock was purchased at an average price of $9.18 per share, for a total transaction of $91,800.00. Following the completion of the purchase, the insider now owns 110,227 shares in the company, valued at $1,011,883.86. The transaction was disclosed in a filing with the SEC, which is available at this link.
Collegium Pharmaceutical Inc (NASDAQ:COLL) traded down 3.08% during trading on Monday, reaching $9.13. The company had a trading volume of 237,704 shares. The stock has a 50 day moving average price of $9.76 and a 200 day moving average price of $14.15. Collegium Pharmaceutical Inc has a 52 week low of $7.37 and a 52 week high of $20.55. The firm’s market capitalization is $267.97 million.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Wednesday, May 10th. The specialty pharmaceutical company reported ($0.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.98) by $0.19. The firm had revenue of $2.17 million for the quarter, compared to analysts’ expectations of $3.55 million. Analysts predict that Collegium Pharmaceutical Inc will post ($3.03) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Collegium Pharmaceutical Inc (COLL) Insider Paul Brannelly Acquires 10,000 Shares” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/05/15/collegium-pharmaceutical-inc-coll-insider-paul-brannelly-acquires-10000-shares.html.
Several large investors have recently bought and sold shares of the company. American International Group Inc. raised its stake in Collegium Pharmaceutical by 27.8% in the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock valued at $100,000 after buying an additional 2,163 shares during the last quarter. Nationwide Fund Advisors raised its stake in Collegium Pharmaceutical by 16.4% in the first quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock valued at $101,000 after buying an additional 1,422 shares during the last quarter. Macquarie Group Ltd. purchased a new stake in Collegium Pharmaceutical during the fourth quarter valued at about $127,000. Partner Investment Management L.P. purchased a new stake in Collegium Pharmaceutical during the third quarter valued at about $138,000. Finally, UBS Group AG raised its stake in Collegium Pharmaceutical by 283.2% in the first quarter. UBS Group AG now owns 13,767 shares of the specialty pharmaceutical company’s stock valued at $139,000 after buying an additional 10,174 shares during the last quarter. 56.60% of the stock is currently owned by institutional investors and hedge funds.
A number of equities analysts have recently issued reports on COLL shares. Jefferies Group LLC restated a “buy” rating and issued a $22.00 price target (down from $24.00) on shares of Collegium Pharmaceutical in a research note on Thursday. Needham & Company LLC lowered their target price on Collegium Pharmaceutical from $28.00 to $25.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, Zacks Investment Research downgraded Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Tuesday, March 14th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $22.40.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc and related companies with MarketBeat.com's FREE daily email newsletter.